Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 4/20 | 0.75 |
| ▸ | TACR3 | P29371 | 14/20 | 0.66 |
| ▸ | TACR2 | P21452 | 9/20 | 0.66 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.66 |
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.59 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5203308 | 0.89 | CYP2C9 (0.61) | CYP2C9TACR3TACR2OPRM1TSHR | |
| SCHEMBL6650281 | 0.89 | TACR3 (0.64) | CYP2C9TACR3TACR2OPRM1TSHR | |
| SCHEMBL6792050 | 0.88 | CYP2C9 (0.60) | CYP2C9TACR3TACR2OPRM1DHODH | |
| SCHEMBL5420737 | 0.86 | TACR3 (0.71) | CYP2C9TACR3TACR2OPRM1NTRK1 | |
| SCHEMBL1581422 | 0.86 | TACR3 (0.63) | CYP2C9TACR3TACR2OPRM1CYP2C19 | |
| SCHEMBL8193060 | 0.86 | TACR3 (0.63) | CYP2C9TACR3TACR2OPRM1CYP2C19 | |
| SCHEMBL14564768 | 0.86 | CYP2C9 (1.00) | CYP2C9TACR3TACR2OPRM1TSHR | |
| SCHEMBL1581137 | 0.85 | TACR3 (0.62) | CYP2C9TACR3TACR2OPRM1NTRK1 | |
| SCHEMBL4667064 | 0.85 | TACR3 (0.67) | CYP2C9TACR3TACR2OPRM1 | |
| SCHEMBL8190048 | 0.85 | TACR3 (0.62) | CYP2C9TACR3TACR2OPRM1NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070259882-A1 | 3-SUBSTITUTED QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 AND NK-2 RECEPTOR ANTAGONISTS | GLAXOSMITHKLINE S.P.A. | 2007-11-08 | — | — | US | disclosed |
| US-20070161647-A1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 and NK-2 RECEPTOR ANTAGONISTS | GLAXOSMITHKLINE S.P.A. | 2007-07-12 | — | — | US | disclosed |
| US-20060229315-A1 | 3-Substituted Quinoline-4-Carboxamide Derivatives as NK-3 and NK-2 Receptor Antagonists | GLAXOSMITHKLINE S.P.A. (IT) | 2006-10-12 | — | — | US | disclosed |
| EP-1659120-A1 | 3-substituted quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists | GlaxoSmithKline S.p.A. (IT) | 2006-05-24 | — | — | EP | disclosed |
| EP-1385839-B1 | 3-SUBSTITUTED QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 AND NK-2 RECEPTOR ANTAGONISTS | GLAXOSMITHKLINE SPA (IT) | 2006-02-22 | — | — | EP | disclosed |
| EP-1377567-B1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 AND NK-2 RECEPTOR ANTAGONISTS | GLAXOSMITHKLINE SPA (IT) | 2005-12-21 | — | — | EP | disclosed |
| US-20050176762-A1 | Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists | GLAXOSMITHKLINE SPA | 2005-08-11 | — | — | US | disclosed |
| US-20040180902-A1 | 3-Substituted quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists | SMITHKLINE BEECHAM S.P.A. (IT) | 2004-09-16 | — | — | US | disclosed |
| US-20040152726-A1 | Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists | SMITHKLINE BEECHAM S.P.A. (IT) | 2004-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180902-A1 | 3-Substituted quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists | HRH4, HRH2, HRH3 | CYP2C9 2713/4885TACR3 60/4885TACR2 6/4885 |
| US-20040152726-A1 | Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists | KCNH2, KCNH3, KCNJ8 | CYP2C9 1099/4885TACR3 149/4885TACR2 56/4885 |
| US-20070161647-A1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 and NK-2 RECEPTOR ANTAGONISTS | KCNQ3, KCNK3, KCNK2 | CYP2C9 1304/4885TACR3 45/4885TACR2 22/4885 |
| US-20070259882-A1 | 3-SUBSTITUTED QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 AND NK-2 RECEPTOR ANTAGONISTS | KCNK3, KCNJ2, KCNK2 | CYP2C9 2151/4885TACR3 19/4885TACR2 12/4885 |
| US-20060229315-A1 | 3-Substituted Quinoline-4-Carboxamide Derivatives as NK-3 and NK-2 Receptor Antagonists | KCNK3, KCNJ2, KCNK2 | CYP2C9 2151/4885TACR3 19/4885TACR2 12/4885 |
| US-20050176762-A1 | Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists | KCNQ3, KCNK3, KCNK2 | CYP2C9 1304/4885TACR3 45/4885TACR2 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.